EXEL Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Also see: EXEL Market Cap History EXEL YTD Return |
EXEL Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Also see: EXEL Market Cap History EXEL YTD Return |
EXEL Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
+7.70% CAGR Mouse over chart for data details
|
EXEL Stock Price Chart |
About Exelixis Inc |
Exelixis is an oncology company that engages in creating medicines and combination regimens for cancer care. Co.'s products include: CABOMETYX® (cabozantinib) tablets, which are approved both alone and in combination with Bristol-Myers Squibb Company's OPDIVO® (nivolumab) for renal cell carcinoma; COMETRIQ® (cabozantinib) capsules, which are approved for progressive, metastatic medullary thyroid cancer; COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan. We show 57 historical shares outstanding datapoints in our coverage of EXEL's shares outstanding history. Understanding the changing numbers of EXEL shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like EXEL versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching EXEL by allowing them to research EXEL shares outstanding history as well as any other stock in our coverage universe. |
EXEL Current Stock Quote |
Free EXEL Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Video: Shares Outstanding Importance | |
|
EXEL Share Performance |
Shares Outstanding Peers |
Exelixis (EXEL) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
EYE Shares Outstanding History |
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.